Application of Box-Behnken design in understanding the quality of genistein self-nanoemulsified drug delivery systems and optimizing its formulation

2009 ◽  
Vol 14 (6) ◽  
pp. 642-649 ◽  
Author(s):  
Saijie Zhu ◽  
Minghuang Hong ◽  
Chen Liu ◽  
Yuanying Pei
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Box Behnken Design

scholarly journals Pancreatic Cancer Related Pain: Review of Pathophysiology and Intrathecal Drug Delivery Systems for Pain Management

2021 ◽  
pp. E583-E594
Keyword(s):  
Quality Of Life ◽  
Drug Delivery ◽  
Pancreatic Cancer ◽  
Pain Management ◽  
Cancer Pain ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Narrative Review ◽  
Intrathecal Drug Delivery

BACKGROUND: Pancreatic cancer (PC) is one of the most lethal cancers and is the eleventh most common cancer worldwide. This disease is characterized by an often-fatal evolution and a high burden of symptoms, particularly pain. Several studies have demonstrated that pancreatic cancer patients have a high prevalence of pain, with up to 82% of patients reporting pain, often requiring systemic strong opioids as mainstay treatment. This comprehensive review of pancreatic cancer related pain (PCRP), focuses on current mechanisms that lead to pain including regional invasion processes, as well as the local secretion of factors that sensitize nociceptive nerves. OBJECTIVE: Our objective was to conduct a review of PCRP and provide updates on intrathecal drug delivery in PC therapeutic recommendations. STUDY DESIGN: We used a narrative review design. We present a novel perspective in the field of pain research by converging data from intrathecal drug delivery trials with previous elements of molecular pain research in PCRP. METHODS: The literature review relating to PCRP pathophysiology and intrathecal drug delivery systems (IDDS) was done with searches of English, French, and Spanish abstracts, using PubMed, Dynamed, EMBASE, SciELO, Uptodate, Google Scholar, and manual searches of the bibliographies of known primary and review articles from IDDS inception until August 2020. Different search strings based on MESH terms were used including: pain, chronic pain, cancer pain, prevalence, pathophysiology, pancreatic cancer, analgesia, invasive pain procedures, celiac plexus neurolysis, pancreatic neuropathy, intrathecal drug delivery, or a combination of these terms. A narrative review based on these sources was prepared. RESULTS: This paper reviews aspects related to pancreatic adenocarcinoma and PCRP prevalence and focuses on recent developments in pathophysiology with IDDS as a pain management strategy. We summarize the best available evidence regarding intrathecal therapy (IT) for PCRP management; 18 studies of IDDS including at least 236 PC patients are analyzed. LIMITATIONS: Some limitations include: IDDS studies heterogeneity regarding disease stage, patient population, and technical aspects, such as catheter placement and treatment regimen, do not allow integration of studies. CONCLUSION: This review analyzes both past and current literature with a critical analysis of findings and respective recommendations. Most studies of IDDS in PCRP evaluate outcomes on pain using one-dimensional pain scales, such as VAS. Other relevant results, such as performance status or quality of life, are not frequently reported. Burden of disease variables, such as cancer stage, location, and comorbidities, like depression and systemic analgesia co-prescription, are usually not presented in these studies. In the same way, most studies do not precisely inform IDDS titration and IT medication. These factors make integration of IDDS in PC studies difficult. Future studies regarding impact of IDDS on pain control on quality of life, in this particular population, may help clinicians in deciding the optimal time and approach for IDDS. The studies should report data on particular disease, comorbidities, and treatment regimens. KEY WORDS: Adenocarcinoma, cancer pain, pain, pancreatic carcinoma, pancreatic neoplasms, pain management, physiopathology, prevalence

Formulation by design of felodipine loaded liquid and solid self nanoemulsifying drug delivery systems using Box–Behnken design

2013 ◽  
Vol 40 (10) ◽  
pp. 1358-1370 ◽  
Author(s):  
Samridhi Verma ◽  
Sandeep Kumar Singh ◽  
Priya Ranjan Prasad Verma ◽  
Mohd Neyaz Ahsan
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Box Behnken Design

The Technology of Self-Emulsifying Drug Delivery Systems

10.12737/3320 ◽  
2014 ◽  
Vol 21 (1) ◽  
pp. 128-133
Author(s):  
Блынская ◽  
E. Blynskaya ◽  
Турчинская ◽  
K. Turchinskaya ◽  
Алексеев ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Aqueous Media ◽  
Delivery Systems ◽  
Solid Dosage ◽  
Show Evidence ◽  
Evaluation Of Parameters ◽  
Semi Solid

Nearly 40% of novel chemical entities show evidence of low solubility in water and low bioavailability. Self-emulsifying formulations have showed the power to improve the bioavailability of hydrophobic drugs. Self-emulsifying formulations belong to lipid formulations, and their size range from 100 nm in case of self-emulsifying drug delivery systems and less than 50 nm in case of self-microemulsifying drug delivery systems. In general self-emulsifying formulations s represent isotropic mixtures of oils, surfactants and co-surfactants, which emulsify spontaneous in aqueous media under conditions of gentle stirring. Usually self-emulsifying formulations presented liquids, which fill the soft gelatinous capsules. However, the dosage form has drawbacks, especially in the production process. In this regard, the use of the methodology of solidification of liquid or semi-solid components of self-emulsifying formulations and their transformation into powders for the preparation of solid dosage forms is relevant. This paper summarizes the main features, a classification of lipid forms, auxiliary substances for the preparation of self-emulsifying formulations, techniques of solidification, the phases of the development of self-emulsifying formulations, evaluation of parameters of quality of liquid and solid self-emulsifying formulations, approaches to development of medicinal forms on the basis of the self-emulsifying formulations, as well as an overview of the drugs, presented on the market in the form of self-emulsifying formulations.

Oral Delivery of Anticancer Agents Using Nanoparticulate Drug Delivery System

2020 ◽  
Vol 20 (14) ◽  
pp. 1132-1140 ◽  
Author(s):  
Prateek Mathur ◽  
Shruti Rawal ◽  
Bhoomika Patel ◽  
Mayur M. Patel
Keyword(s):  
Quality Of Life ◽  
Drug Delivery ◽  
Anticancer Agents ◽  
Oral Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Intravenous Route ◽  
Cost Of Treatment ◽  
Anti Cancer

Background: Conventionally, anti-cancer agents were administered through the intravenous route. The major drawbacks associated with the intravenous route of administration are: severe side effects, need of hospitalization, nursing care, and palliative treatment. In order to overcome the drawbacks associated with the intravenous route of administration, oral delivery of anti-cancer agents has gained tremendous interest among the scientific fraternity. Oral delivery of anti-cancer agents principally leads to a reduction in the overall cost of treatment, and aids in improving the quality of life of patients. Bioavailability of drugs and inter-subject variability are the major concerns with oral administration of anti-cancer agents. Factors viz. physicochemical and biological barriers (pre-systemic metabolism and transmembrane efflux of the drug) are accountable for hampering oral bioavailability of anti-cancer agents can be efficiently overcome by employing nanocarrier based drug delivery systems. Oral delivery of anticancer agents by employing these drug delivery systems will not only improve the quality of life of patients but will also provide pharmacoeconomic advantage and lead to a reduction in the overall cost of treatment of life-threatening disease like cancer. Objective: This article aims to familiarize the readers with some of the recent advancements in the field of nanobased drug delivery systems for oral delivery of anticancer agents. Conclusion: Advancement in the field of nanotechnology-based drug delivery systems has opened up gateways for the delivery of drugs that are difficult to administer orally. Oral delivery of anti-cancer agents by these drug delivery systems will not only improve the quality of life of patients but will also provide pharmacoeconomic advantage and lead to a reduction in the overall cost of treatment of life-threatening disease like cancer.

scholarly journals Nanocarriers as a Tool for the Treatment of Colorectal Cancer

Pharmaceutics ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1321
Author(s):  
Ana Luiza C. de S. L. Oliveira ◽  
Timo Schomann ◽  
Lioe-Fee de Geus-Oei ◽  
Ellen Kapiteijn ◽  
Luis J. Cruz ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Drug Delivery ◽  
Effective Treatment ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Treatment Efficiency ◽  
The Past ◽  
Promising Tool ◽  
Great Hope

Nanotechnology is a promising tool for the treatment of cancer. In the past decades, major steps have been made to bring nanotechnology into the clinic in the form of nanoparticle-based drug delivery systems. The great hope of drug delivery systems is to reduce the side effects of chemotherapeutics while simultaneously increasing the efficiency of the therapy. An increased treatment efficiency would greatly benefit the quality of life as well as the life expectancy of cancer patients. However, besides its many advantages, nanomedicines have to face several challenges and hurdles before they can be used for the effective treatment of tumors. Here, we give an overview of the hallmarks of cancer, especially colorectal cancer, and discuss biological barriers as well as how drug delivery systems can be utilized for the effective treatment of tumors and metastases.

Intelligent drug delivery systems for the treatment of solid tumors

2016 ◽  
Vol 8 (1) ◽  
Author(s):  
Triantafyllos Stylianopoulos
Keyword(s):  
Drug Delivery ◽  
Adverse Effects ◽  
Solid Tumors ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Homogeneous Distribution ◽  
Design Considerations ◽  
Therapeutic Outcomes ◽  
Selective Delivery

AbstractThe rationale for the use of nanoparticle formulations to treat cancer is based on the ability of these particles to facilitate selective delivery of drugs to the tumor site, reducing adverse effects and improving therapeutic outcomes. Current clinically approved nanomedicines have managed to reduce adverse effects significantly but the increase in overall survival is modest in many cases. Therefore, even though the goal of a better quality of life for the cancer patients has been achieved in large part, the increase in life expectancy still remains a critical challenge. Abnormalities in the tumor micro-environment prevent homogeneous distribution of nanoparticles to the interior of the tumor, decreasing the efficacy of the drug. Intelligent drug delivery systems offer new hope for overcoming these physiological barriers posed by the tumor and have the potential to provide more effective treatments. This review discusses the barriers to the delivery of nanomedicines to solid tumors, suggests design considerations that could optimize delivery and reviews promising intelligent drug delivery systems that have been developed to date.

scholarly journals Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects

Nanomaterials ◽  
2020 ◽  
Vol 10 (7) ◽  
pp. 1403 ◽  
Author(s):  
Belén Begines ◽  
Tamara Ortiz ◽  
María Pérez-Aranda ◽  
Guillermo Martínez ◽  
Manuel Merinero ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Polymeric Nanoparticles ◽  
Life Quality ◽  
Delivery Systems ◽  
Future Prospects ◽  
Drug Bioavailability ◽  
Site Of Action ◽  
Recent Developments

The complexity of some diseases—as well as the inherent toxicity of certain drugs—has led to an increasing interest in the development and optimization of drug-delivery systems. Polymeric nanoparticles stand out as a key tool to improve drug bioavailability or specific delivery at the site of action. The versatility of polymers makes them potentially ideal for fulfilling the requirements of each particular drug-delivery system. In this review, a summary of the state-of-the-art panorama of polymeric nanoparticles as drug-delivery systems has been conducted, focusing mainly on those applications in which the corresponding disease involves an important morbidity, a considerable reduction in the life quality of patients—or even a high mortality. A revision of the use of polymeric nanoparticles for ocular drug delivery, for cancer diagnosis and treatment, as well as nutraceutical delivery, was carried out, and a short discussion about future prospects of these systems is included.

Techniques For The Preparation of Tissue Samples Containing Injectable Polymer Microcapsules

1985 ◽  
Vol 43 ◽  
pp. 710-711
Author(s):  
G.E. Visscher ◽  
R. L. Robison ◽  
G. J. Argentieri
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Gastrocnemius Muscle ◽  
Degradation Process ◽  
Delivery Systems ◽  
Tissue Reaction ◽  
Electron Microscopic ◽  
Tissue Samples ◽  
Injectable Polymer ◽  
Microscopic Techniques

The use of various bioerodable polymers as drug delivery systems has gained considerable interest in recent years. Among some of the shapes used as delivery systems are films, rods and microcapsules. The work presented here will deal with the techniques we have utilized for the analysis of the tissue reaction to and actual biodegradation of injectable microcapsules. This work has utilized light microscopic (LM), transmission (TEM) and scanning (SEM) electron microscopic techniques. The design of our studies has utilized methodology that would; 1. best characterize the actual degradation process without artifacts introduced by fixation procedures and 2. allow for reproducible results.In our studies, the gastrocnemius muscle of the rat was chosen as the injection site. Prior to the injection of microcapsules the skin above the sites was shaved and tattooed for later recognition and recovery. 1.0 cc syringes were loaded with the desired quantity of microcapsules and the vehicle (0.5% hydroxypropylmethycellulose) drawn up. The syringes were agitated to suspend the microcapsules in the injection vehicle.

Sign in / Sign up

Export Citation Format

Share Document